Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.36 +2.61%
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- TaiMed Biologics gets TFDA drug license notice for HIV therapy Trogarzo
- Cosmos Health posts 31% revenue gain in Q2 and H1 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
